SK pharmteco to Manufacture AaviGen’s Lead Gene Therapy for Heart Failure

• SK pharmteco has entered a multi-year manufacturing agreement with AaviGen for its lead gene therapy product AVG-101, targeting heart failure.

• The partnership leverages SK pharmteco’s expertise in viral vector manufacturing to support AaviGen’s preclinical gene therapy development.

SK pharmteco, a global contract development and manufacturing organisation (CDMO), has announced a multi-year agreement with biotechnology firm AaviGen GmbH. The agreement appoints SK pharmteco as the preferred manufacturing partner for AaviGen’s lead gene therapy product AVG-101, aimed at treating heart failure.

This collaboration supports AaviGen’s proprietary adeno-associated viral vector technology, which targets molecular causes of heart muscle dysfunction. The gene therapy focuses on improving cardioprotection, contractility, and energy metabolism in patients with heart failure.

Patrick Most, CEO of AaviGen, said, “SK pharmteco is a key partner for AaviGen as part of our strategy to develop and commercialise innovative gene therapies against diseases of the cardiovascular system. We look forward to the collaboration with great confidence.”

The deal aligns with SK pharmteco’s expertise in viral vector manufacturing, with Patrick Mahieux, President of Cell and Gene, Europe, stating, “Our deep expertise in viral vector manufacturing and our commitment to quality make us the ideal partner to support this promising therapy.”

Martin Busch, PhD., COO of AaviGen added: “SK pharmteco stands out from the global pool of suppliers because of its extensive experience in process development and manufacturing of adeno-associated viral-based gene therapies.